Enhanced uptake and photoactivation of topical methyl aminolevulinate after fractional CO 2 laser pretreatment

Lasers in Surgery and Medicine

Volumn 43, Issue 8, 2011, Pages 804-813

  Haedersdal M ^a,b   Katsnelson, J ^a   Sakamoto, F H ^a,c   Farinelli, W A ^a   Doukas, A G ^a   Tam, J ^a   Anderson, R R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

drug delivery; fractional laser ablation; methyl 5 aminolevulinic acid; photodynamic therapy; photosensitizer; porphyrins

Indexed keywords

AMINOLEVULINIC ACID METHYL ESTER; PORPHYRIN;

ABLATIVE FRACTIONAL LASER RESURFACING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLEACHING; CARBON DIOXIDE LASER; CONTROLLED STUDY; DERMIS; DRUG UPTAKE; EPIDERMIS; ERYTHEMA; EXPERIMENTAL PIG; FLUORESCENCE; HAIR FOLLICLE; LIGHT INTENSITY; LOW LEVEL LASER THERAPY; MALE; NONHUMAN; PHOTOACTIVATION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; SKIN PENETRATION; SKIN SWELLING; SUBCUTANEOUS FAT;

ADMINISTRATION, TOPICAL; AMINOLEVULINIC ACID; ANIMALS; COMBINED MODALITY THERAPY; LASERS, GAS; MALE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; SKIN; SUS SCROFA;

EID: 80053480696     PISSN: 01968092     EISSN: 10969101     Source Type: Journal    
DOI: 10.1002/lsm.21096     Document Type: Article

References (32)

1. Trakatelli M, Ulrich C, del Marmol V, et al. Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: Accurate and comparable data are needed for effective public health monitoring and interventions. Br J Dermatol 2007; 156: 1-7. (Pubitemid 46646534)
2. Neville JA, Welch E, Leffell DJ,. Management of nonmelanoma skin cancer in 2007. Nat Clin Pract Oncol 2007; 4: 462-469. (Pubitemid 47393802)
3. Leiter U, Garbe C,. Epidemiology of melanoma and nonmelanoma skin cancerâThe role of sunlight. Adv Exp Med Biol 2008; 624: 89-103.
4. Braathen LR, Szeimies RM, Basset-Seguin N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: An international consensus. J Am Acad Dermatol 2007; 56: 125-143. (Pubitemid 44969292)
5. Morton CA, McKenna KE, Rhodes LE,. Guidelines for topical photodynamic therapy: Update. Br J Dermatol 2008; 159: 1245-1266.
6. Kennedy JC, Pottier RH, Pross DC,. Photodynamic therapy with endogenous protoporphyrin IX: Basic principles and present clinical experience. J Photochem Photobiol B 1990; 6: 143-148.
7. Kennedy JC, Pottier RH,. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B 1992; 14: 275-292.
8. Ortel B, Calzavara-Pinton P,. Molecular mechanisms of photodynamic therapy. Front Biosci 2009; 14: 4157-4172.
9. Robinson DJ, de Bruijn HS, van der Veen N, Stringer MR, Brown SB, Star WM,. Fluorescence photobleaching of ALA-induced protoporphyrin IX during photodynamic therapy of normal hairless mouse skin: The effect of light dose and irradiance and the resultant biological effect. Photochem Photobiol 1998; 67: 140-149. (Pubitemid 128471972)
10. Szeimies RM, Karrer S, Radakovic-Fijan S, Tanew A, Calzavara-Pinton G, Zane C, Sideroff A, Hempel M, Ulrich J, Proebstle T, Meffert H, Mulder M, Salomon D,. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: A prospective, randomized study. J Am Acad Dermatol 2002; 47: 258-262.
11. Horn M, Wolf P, Wulf HC, Warloe T, Fritsch C, Rhodes LE, et al. Topical methyl aminolevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional therapy. Br J Dermatol 2003; 149: 1242-1249. (Pubitemid 38058101)
12. Rhodes LE, de Rie MA, Leifsdottir R, et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol 2007; 143: 1131-1136. (Pubitemid 47443364)
13. Vinciullo C, Elliott T, Francis D, et al. Photodynamic therapy with topical methyl aminolevulinate for "difficult to treat" basal cell carcinoma. Br J Dermatol 2005; 152: 765-772. (Pubitemid 40571312)
14. Foley P, Freeman M, Menter A, Siller G, et al. Photodymanmic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: Results of two randomized studies. Int J Dermatol 2009; 48: 1236-1245.
15. Morton CA, MacKie RM, Whitehurst C, et al. Photodynamic therapy for basal cell carcinoma: Effect of tumor thickness and duration of photosensitizer application on response. Arch Dermatol 1998; 134: 248-249. (Pubitemid 28119687)
16. Martin A, Tope WD, Grevelink JM, et al. Lack of selectivity of protoporphyrin IX fluorescence for basal cell carcinoma after topical application of 5-aminolevulinic acid: Implications for photodynamic treatment. Arch Dermatol Res 1995; 287: 665-674.
17. Sandberg C, Halldin CB, Ericson MB, et al. Bioavailability of aminolevulinic acid and methylaminolevulinate in basal cell carcinomas: A perfusion study using microdialysis in vivo. Br J Dermatol 2008; 159: 1170-1176.
18. Angell-Petersen E, SÃrensen R, Warloe T, Soler AM, Moan J, Peng Q, Giercksky KE,. Porphyrin formation in actinic keratosos and basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Invest Dermatol 2006; 126: 265-271. (Pubitemid 43323159)
19. Peng Q, Soler AM, Warloe T, Nesland JM, Giercksky KE,. Selective distribution of porphyrins in skin thick basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Photochem Photobiol B 2001; 62: 140-145. (Pubitemid 32898834)
20. Gerritsen MJP, Smits T, Kleinpenning MM, et al. Pretreatment to enhance protoporphyrin IX accumulation in photodynamic therapy. Dermatology 2009; 218: 193-202.
21. 2 laser-assisted drug delivery. Lasers Surg Med 2010; 42: 113-122.
22. Manstein D, Herron GS, Sink RK, et al. Fractional photothermolysis: A new concept for cutaneous remodeling using microscopic patterns of thermal injury. Lasers Surg Med 2004; 34: 426-438. (Pubitemid 38890753)
23. Laubach HJ, Tannous Z, Anderson RR, et al. Skin responses to fractional photothermolysis. Lasers Surg Med 2006; 38: 142-149.
24. Helbig D, Bodendorf M, Grunewald S, et al. Immunohistochemical investigation of wound healing in response to fractional photothermolysis. J Biomed Optics 2009; 14: 064044-1-064044-8.
25. Tannous Z,. Fractional resurfacing. Clin Dermatol 2007; 25: 480-486. (Pubitemid 47385080)
26. Moseley H,. Light distribution and calibration of commercial PDT LED arrays. Photochem Photobiol Sci 2005; 4: 911-914. (Pubitemid 41686583)
27. Tarstedt M, Rosdahl I, Berne B, Svamberg K, Wennberg AM,. A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp. Acta Derm Venereol 2005; 85: 424-428. (Pubitemid 41345617)
28. Wiegell SR, HÃ∥dersdal M, Eriksen P, Wulf HC,. Photodynamic therapy of actinic keratoses with 8% and 16% methyl aminolevulinate and home-based daylight exposure: A double-blinded randomized clinical trial. Br J Dermatol 2009; 160: 1308-1314.
29. Oseroff AR, Shieh S, Frawley NP, et al. Treatment of diffuse basal cell carcinomas and basaloid follicular hamartomas in nevoid basal cell carcinoma syndrome by wide-area 5-aminolevulinic acid photodynamic therapy. Arch. Dermatol 2005; 141: 60-67. (Pubitemid 40144441)
30. Wiegell SR, Skiveren J, Phillipsen PA, Wulf HC,. Pain during photodynamic therapy is associated with protoporphyrin IX fluorescence and fluence rate. Br J Derm 2008; 158: 727-733. (Pubitemid 351415749)
31. Cottrell WJ, Paquette AD, Keymel KR, et al. Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. Clin Cancer Res 2008; 14: 4475-4483.
32. Mikolajewska P, Donnelly RF, Garland MJ, et al. Microneedle pre-treatment of human skin improves 5-aminolevulinic acid (ALA)- and 5-aminolevulinic acid methyl ester (MAL)-induced PpIX production for topical photodynamic therapy without increase in pain or erythema. Pharm Res 2010; 27: 2213-2220.